Literature DB >> 29968427

Toll-like receptors TLR-2, TLR-4, TLR-7, and TLR-9 in tumor tissue and serum of the patients with esophageal squamous cell carcinoma and gastro-esophageal junction cancer.

Dorota Diakowska1, Mirosław Nienartowicz2, Krzysztof Grabowski2, Joanna Rosińczuk1, Małgorzata Krzystek-Korpacka3.   

Abstract

BACKGROUND: Stimulation of toll-like receptors (TLRs) has been linked to the development of esophageal and gastric cancers.
OBJECTIVES: The aim of the study was to evaluate the clinical significance of tissue expression and serum concentration of TLR-2, TLR-4, TLR-7 and TLR-9 in patients with esophageal squamous cell carcinoma and gastro-esophageal junction adenocarcinoma.
MATERIAL AND METHODS: The study group consisted of 97 individuals: 32 with esophageal squamous cell carcinoma, 27 with gastro-esophageal junction cancer, and 38 ageand gender-matched controls. The mRNA expression and protein concentration of TLRs in tissues and sera were measured by reverse transcription polymerase chain reaction (RT-PCR) and enzyme-linked immunosorbent assay (ELISA) tests.
RESULTS: In esophageal cancer patients, mRNA expressions of TLR-2, TLR-4 and TLR-7, and protein concentrations of all TLRs were significantly higher in tumor than in control tissue (p < 0.05). In esophageal cancer patients with lymph node metastasis, a tendency toward higher protein concentrations of tumor TLR-4 was observed. In gastro-esophageal junction adenocarcinoma subgroup, only the mRNA expression of TLR-7 and protein concentrations of TLR-4, TLR-7 and TLR-9 were significantly higher in tumors than in normal mucosa (p < 0.05). Protein concentration of TLR-9 was significantly higher in tumors of gastro-esophageal junction cancer with lymph node metastasis and depth of tumor invasion. Diagnostic potential of serum TLR-4 as a marker of gastro-esophageal junction cancer presence was reported.
CONCLUSIONS: We demonstrated differences in the expression patterns of TLRs between esophageal squamous cell carcinoma and adenocarcinoma of gastro-esophageal junction, and showed circulating TLR-4 to be a potential marker of gastro-esophageal junction cancer.

Entities:  

Keywords:  biomarkers; gastro-esophageal cancer; toll-like receptors

Mesh:

Substances:

Year:  2019        PMID: 29968427     DOI: 10.17219/acem/87012

Source DB:  PubMed          Journal:  Adv Clin Exp Med        ISSN: 1899-5276            Impact factor:   1.727


  6 in total

1.  WGCNA identification of TLR7 as a novel diagnostic biomarker, progression and prognostic indicator, and immunotherapeutic target for stomach adenocarcinoma.

Authors:  Qihang Yuan; Qi Zhou; Jie Ren; Guan Wang; Chunlai Yin; Dong Shang; Shilin Xia
Journal:  Cancer Med       Date:  2021-05-12       Impact factor: 4.452

2.  Role of Toll like receptor in progression and suppression of oral squamous cell carcinoma.

Authors:  Yash Sharma; Kumud Bala
Journal:  Oncol Rev       Date:  2020-05-19

3.  Activation of Toll-like receptor 2 enhances peripheral and tumor-infiltrating CD8+ T cell cytotoxicity in patients with gastric cancer.

Authors:  Junli Xu; Rongya Guo; Jing Jia; Yun He; Shuixiang He
Journal:  BMC Immunol       Date:  2021-10-07       Impact factor: 3.615

4.  TLR3 Serves as a Prognostic Biomarker and Associates with Immune Infiltration in the Renal Clear Cell Carcinoma Microenvironment.

Authors:  Guodong Liao; Jia Lv; Alin Ji; Shuai Meng; Chao Chen
Journal:  J Oncol       Date:  2021-09-06       Impact factor: 4.375

5.  Curcumin plays a protective role against septic acute kidney injury by regulating the TLR9 signaling pathway.

Authors:  Huiqing Li; Hui Sun; Yaru Xu; Guihua Xing; Xuehui Wang
Journal:  Transl Androl Urol       Date:  2021-05

6.  Mucosa-Associated Microbiota in Barrett's Esophagus, Dysplasia, and Esophageal Adenocarcinoma Differ Similarly Compared With Healthy Controls.

Authors:  Shajan Peter; Amanda Pendergraft; William VanDerPol; C Mel Wilcox; Kondal R Kyanam Kabir Baig; Casey Morrow; Jacques Izard; Peter J Mannon
Journal:  Clin Transl Gastroenterol       Date:  2020-08       Impact factor: 4.396

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.